Within the framework of this research, the diagnostic significance of serum tau and NfL in early-time Alzheimer’s disease (AD) was investigated through screening of healthy individuals and patients with early AD. Within the framework of this study, there were 200 participants screened, out of which patients with early stages of AD and their age-matched counterparts made two groups. Serum tau and NfL organizational and clinical biorepositories were prepared according to ELISA and ROC methods respectively. A significant difference in the level of tau serum (p<0.01) and NfL (p < 0.01) was found in AD patients when compared with controls. The AUC values for tau and NfL were 0.87 and 0.9 respectively establishing the biomarkers as potent. Blood tau and NfL levels are useful non-invasive techniques to detect AD in asymptomatic patients with NfL being slightly more sensitive than tau. Further research needs to identify whether the two are more effective when used singly or in combination.